Terms: = Endocrine gland cancer AND GATA2, NFE1B, 2624, ENSG00000179348, MGC2306, P23769 AND Diagnosis
4 results:
1. Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives.
Wan XY; Chen J; Wang JW; Liu YC; Shu K; Lei T
Curr Med Sci; 2022 Dec; 42(6):1111-1118. PubMed ID: 36544040
[TBL] [Abstract] [Full Text] [Related]
2. Pituitary Gangliocytoma Producing TSH and TRH: A Review of "Gangliocytomas of the Sellar Region".
Sakata K; Fujimori K; Komaki S; Furuta T; Sugita Y; Ashida K; Nomura M; Morioka M
J Clin Endocrinol Metab; 2020 Oct; 105(10):3109-21. PubMed ID: 32706866
[TBL] [Abstract] [Full Text] [Related]
3. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O; Kefeli M; Çalışkan S; Asa SL
Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
[TBL] [Abstract] [Full Text] [Related]
4. Comparative effectiveness of elastographic and B-mode ultrasound criteria for diagnostic discrimination of thyroid nodules: a meta-analysis.
Razavi SA; Hadduck TA; Sadigh G; Dwamena BA
AJR Am J Roentgenol; 2013 Jun; 200(6):1317-26. PubMed ID: 23701071
[TBL] [Abstract] [Full Text] [Related]
